Please assess the completion status of the following clinical trial:

Trial Title: Individualized High Dose Methotrexate to Treat Cancer in Children Who Have a Significant Risk for Side Effects to Methotrexate

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Age: Patients must be greater than or equal to 365 days and less than 23 years of age at the time of enrollment.~2. Diagnosis: Patients with any malignancy who will receive high dose methotrexate (HDMTX) given as a 5 g/m2 infusion over 24 hours and a history of ≥ 1 of the following:~   * Documented decreased renal function, defined as Creatinine greater than 1.5 x baseline or glomerular filtration rate (GFR) \<65ml/min/1.73m2.~  * History of prior nephrotoxicity with HDMTX as evidence by increased creatinine to 1.5 x baseline or need for dialysis or carboxypeptidase~  * History of Grade 3 adverse event (AE) related to HDMTX (mucositis, myelosuppression, nephrotoxicity, hepatotoxicity) based on the NIH Common Terminology Criteria for Adverse Events (CTCAE) version 4.0~  * Provider concern patient is at risk for MTX toxicity, such as a prior history of treatment with nephrotoxic chemotherapy, history of HDMTX-related neurotoxicity, or antimicrobial/antifungal therapy~Exclusion Criteria:~1. Unable to draw labs for HDMTX serum concentration~2. Enrollment on a protocol (COG or other) which restricts proposed dose modifications~3. Patients with Trisomy 21~4. Patients with greater than grade 1 neurologic toxicity at the time of enrollment that is attributed to unresolved prior methotrexate toxicity~5. Patients with greater than or equal to grade 3 chronic kidney disease at enrollment (eGFR or creatine clearance (CrCl) less than 30ml/min/1.73m2)

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 22 Years
- Healthy Volunteers: f

Study Arms:
- Individualized High Dose Methotrexate (Type: EXPERIMENTAL): Individualized high dose methotrexate given as a 24-hour infusion.

Based on this trial design, predict the completion outcome and termination type (if applicable).